Advertisement

December 2018

Volume 17Issue 12p2297-2545
Open Access
On the Cover: Midostaurin displays anticancer activity in non-small cell lung cancer through inhibition of non-canonical targets. Functional proteomics comprised of chemical and phosphoproteomics and subsequent interrogation of the functional effector network reveals a complex polypharmacology mechanism of action and enables the rational design of a synergistic drug combination. For details, see the article by Ctortecka et al., 2434–2447....
On the Cover: Midostaurin displays anticancer activity in non-small cell lung cancer through inhibition of non-canonical targets. Functional proteomics comprised of chemical and phosphoproteomics and subsequent interrogation of the functional effector network reveals a complex polypharmacology mechanism of action and enables the rational design of a synergistic drug combination. For details, see the article by Ctortecka et al., 2434–2447.

Research

Technological Innovation and Resources

Advertisement